ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Old drug with new application: spironolactone suppresses Panx 1-mediated Ca
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
rationaleAtherosclerosis (AS) is a chronic inflammatory disease of the arterial walls, initiated by endothelial dysfunction and subendothelial lipid deposition. Even though treatments to lower lipids have improved, there are still not many options that specifically tackle inflammation-caused endothelial dysfunction in the early stage of AS. Spironolactone (SP) has been shown to be beneficial in reducing cardiovascular complications, and while it acts as a pharmacological inhibitor of pannexin 1 (Panx 1), the mechanism by which SP modulates Panx 1 in endothelial cells (ECs) during inflammation remains unclear.
objectiveTo identify Panx 1 on ECs is a key mediator through which SP ameliorates vascular inflammation, lowers oleic acid (OA)-induced intracellular neutral lipid accumulation, and sustains the function of ECs, thereby attenuating early AS. METHODS AND
resultsIn vivo, SP administration significantly ameliorated plasma biochemical parameters, mitigate aortic inflammation and reduced lipid deposition, thereby reducing endothelial activation and alleviating endothelium damage in an early AS model established by feeding ApoE
conclusionTaken together, these findings indicate that SP mitigates early AS by reduced endothelial activation and attenuating inflammation-driven intracellular neutral lipid accumulation via suppression of the Panx 1/Ca
Indexed as
Identifiers
42734843What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.